Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > News > Canaccord Adams Initiates Coverage on AMAG Pharmaceuticals (AMAG) with a Buy

October 16th, 2008

Canaccord Adams Initiates Coverage on AMAG Pharmaceuticals (AMAG) with a Buy

Abstract:
Canaccord Adams initiates coverage on AMAG Pharmaceuticals (Nasdaq: AMAG) with a Buy rating and $57 target.

Canaccord analyst says, "Binary event but we believe data should enable first cycle approval...We acknowledge that there is controversy about whether AMAG has generated enough data for ferumoxytol approval. We believe that the Phase 3 studies demonstrated the strong efficacy and (more importantly) clean safety profile of ferumoxytol in CKD patients. We think that data also suggests that ferumoxytol may have the best safety profile, and importantly the lowest rates of anaphylaxis, of all the IV iron therapies. However, given the conservative FDA environment, we recognize that AMAG could receive a late approval or a request for more data...We believe that AMAG shares offer a compelling risk/benefit profile. AMAG shares are down almost 50% from their 52-week high in October 2007. We base our $57 price target on a pNPV analysis that assumes a 50% probability of a first-cycle approval for ferumoxytol. If ferumoxytol is approved, our pNPV analysis would yield a $95 value. If the FDA requests an additional study, our pNPV analysis would yield a $25 value."

Source:
streetinsider.com

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Researchers develop artificial building blocks of life March 8th, 2024

How surface roughness influences the adhesion of soft materials: Research team discovers universal mechanism that leads to adhesion hysteresis in soft materials March 8th, 2024

Two-dimensional bimetallic selenium-containing metal-organic frameworks and their calcinated derivatives as electrocatalysts for overall water splitting March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

Investments/IPO's/Splits

Daikin Industries becomes OCSiAl shareholder July 27th, 2021

180 Degree Capital Corp. Reports +14.2% Growth in Q1 2021, $10.60 Net Asset Value Per Share as of March 31, 2021, and Developments From Q2 2021 May 11th, 2021

INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021

180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021

Nanomedicine

High-tech 'paint' could spare patients repeated surgeries March 8th, 2024

Researchers develop artificial building blocks of life March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

The Access to Advanced Health Institute receives up to $12.7 million to develop novel nanoalum adjuvant formulation for better protection against tuberculosis and pandemic influenza March 8th, 2024

Announcements

What heat can tell us about battery chemistry: using the Peltier effect to study lithium-ion cells March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

The Access to Advanced Health Institute receives up to $12.7 million to develop novel nanoalum adjuvant formulation for better protection against tuberculosis and pandemic influenza March 8th, 2024

Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project